Skip to main navigation
  • Contact Us
Xen 01
  • About Us
    • Management
    • Partnering
    • Board of Directors
  • Pipeline
    • Vudalimab (PD-1 x CTLA-4)
    • XmAb819 (ENPP3 x CD3)
    • XmAb808 (B7-H3 x CD28)
    • XmAb541 (CLDN6 x CD3)
    • Plamotamab (CD20 x CD3)
    • XmAb942 (Xtend TL1A)
    • XmAb657 (CD19 x CD3)
  • Technology
    • Bispecific Fc Domains
    • Cytotoxic Fc Domains
    • Immune Inhibitor Fc Domains
    • Xtend Fc Domains
    • Publications
  • Clinical Trials
    • Expanded Access Policy
  • Investors
    • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Corporate Responsibility
    • Financials & Filings
      • SEC Filings
      • Annual Reports
    • Analyst Coverage
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
    • Investor FAQs
    • Contact Us
    • Email Alerts
  • Careers
    • Opportunities

You are here:
Home / Investors / / REGDEX

Investor Relations

  • Investors
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Corporate Responsibility
  • Financials & Filings
  • Analyst Coverage
  • Stock Information
  • Investor FAQs
  • Contact Us
  • Email Alerts

Tools

Shareholder Tools

  • Snaphot
  • Print
  • Share
  • Facebook
  • LinkedIn
  • Twitter
  • RSS

SEC Filing Details

Document Details

Form
REGDEX
Filing Date
May 6, 2005
Document Date
May 6, 2005
Form Description
REGDEX
Filing Group
Other
Company
Xencor, Inc.
Issuer
Xencor Inc
Xencor © Copyright 2024 | Privacy Policy
Scroll to top